RARE
Ultragenyx PharmaceuticalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful readouts and regulatory progress validate pricing for niche indications, enabling meaningful re-rating and significant upside from current levels.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.2.
What can break
Clinical trial failure or negative topline
Momentum
88
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $23.10 · Bull $46.20 · Bear $11.55
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $53.26
Why
Momentum88 · Δ7d -3.2
Value41 · Δ7d +0.0
Sentiment34 · Δ7d +9.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendSoftening
Δ7d
-3.2
Δ21d
+11.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
34
34% active weight
Current posture
7d trendImproving
Δ7d
+9.0
Δ21d
+2.4
Why this grade
Composite grade C. Momentum 88.2 / Value 41.1 / Sentiment 34.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$2.81B
Beta
0.16
Shares Out
98.49M
P/E (TTM) · Derived
-4.9
P/S (TTM)
3.54
P/FCF (TTM) · Derived
-5.67
Rev YoY
-2.4%
EPS YoY
+17.2%
Gross Margin
+78.5%
Op Margin
-86.3%
Net Debt
$559M
Current Ratio
2.02
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology